Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1
AACE Endocrinology and Diabetes · 2026-09
DOI: 10.1016/j.aed.2026.07.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Ugur Ayar und 7 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Ayar, U., Akurati, S., Petridis, S., Mejia, H., Udayakumar, V., Punjabi, N., Bernal-Mizrachi, E., & Varghese, R. T. (2026). Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1. AACE Endocrinology and Diabetes. https://doi.org/10.1016/j.aed.2026.07.024
Vancouver
Ayar U, Akurati S, Petridis S, Mejia H, Udayakumar V, Punjabi N, et al. Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1. AACE Endocrinology and Diabetes. 2026. doi:10.1016/j.aed.2026.07.024
BibTeX
@article{Ayar2026,
author = {Ayar, Ugur and Akurati, Sneha and Petridis, Samuele and Mejia, Hery and Udayakumar, Varsha and Punjabi, Naresh and Bernal-Mizrachi, Ernesto and Varghese, Ron T.},
title = {Clinical Decision-Making for Incretin-Based Therapy in Neurofibromatosis Type 1},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
doi = {10.1016/j.aed.2026.07.024}
}
EUVIMED